Try our Advanced Search for more refined results
IN RE: Intercept Pharmaceuticals, Inc. Securities Litigation
Case Number:
1:14-cv-01123
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
May 06, 2016
Intercept To Pay $55M To End Investors' Stock-Drop MDL
Intercept Pharmaceuticals Inc. will fork over $55 million to resolve multidistrict litigation brought by investors accusing it of securities fraud by concealing a liver drug's side effects, according to a stipulation filed Thursday in New York federal court.
-
March 05, 2015
Intercept Can't Dodge Investors' Stock Drop MDL
A New York federal judge on Wednesday refused to dismiss multidistrict litigation brought by investors accusing Intercept Pharmaceuticals Inc. of securities fraud, finding the investors provided evidence that the company and its executives knowingly concealed a liver drug's side effects.